Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis
S Paul, AC Moreau, E Del Tedesco… - Inflammatory bowel …, 2014 - academic.oup.com
Background The aim of this meta-analysis was to explore the magnitude of the association
between pharmacokinetics of adalimumab and clinical response in patients with …
between pharmacokinetics of adalimumab and clinical response in patients with …
Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response
GR Lichtenstein - Therapeutic advances in gastroenterology, 2013 - journals.sagepub.com
Antitumor necrosis factor α (anti-TNF) agents have dramatically influenced management of
refractory inflammatory bowel disease (IBD). However, not all patients respond to treatment …
refractory inflammatory bowel disease (IBD). However, not all patients respond to treatment …
Effects of combination therapy with immunomodulators on trough levels and antibodies against tumor necrosis factor antagonists in patients with inflammatory bowel …
Y Qiu, R Mao, B Chen, S Zhang, J Guo, Y He… - Clinical …, 2017 - Elsevier
Background & Aims It is not clear whether combination therapy with immunomodulators
affects the immunogenicity of tumor necrosis factor (TNF) antagonists in patients with …
affects the immunogenicity of tumor necrosis factor (TNF) antagonists in patients with …
[HTML][HTML] Therapeutic drug monitoring of TNF antagonists in inflammatory bowel disease
R Khanna, BG Levesque, WJ Sandborn… - Gastroenterology & …, 2014 - ncbi.nlm.nih.gov
Although tumor necrosis factor (TNF)-α antagonists play a critical role in the treatment of
moderate-to-severe inflammatory bowel disease (IBD), several factors can impact treatment …
moderate-to-severe inflammatory bowel disease (IBD), several factors can impact treatment …
Current and future status of therapeutic drug monitoring in the treatment of IBD
R Khanna, BG Feagan - Current treatment options in gastroenterology, 2014 - Springer
Opinion statement Although tumor necrosis factor (TNF)-antagonists are highly effective
agents for the treatment of inflammatory bowel diseases (IBD), up to 40% of patients …
agents for the treatment of inflammatory bowel diseases (IBD), up to 40% of patients …
Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort …
RD Little, IE Chu, EP van der Zanden… - Journal of Crohn's …, 2019 - academic.oup.com
Background Adalimumab is administered via a pre-filled syringe or spring-loaded pen. In a
previous study in Crohn's disease, higher drug levels were observed in syringe users. The …
previous study in Crohn's disease, higher drug levels were observed in syringe users. The …
Utilidad de la monitorización de niveles de fármaco en la optimización del tratamiento biológico en la enfermedad inflamatoria intestinal
FM Vera Rivero - 2016 - riuma.uma.es
El 15% de los pacientes con enfermedad de Crohn (EC) y de colitis ulcerosa (CU) está en
tratamiento con fármacos biológicos. Los anti TNF son de primera línea. Un 30% no …
tratamiento con fármacos biológicos. Los anti TNF son de primera línea. Un 30% no …
Role of therapeutic drug monitoring for biologics in IBD
The introduction of monoclonal antibody therapy directed against tumor necrosis factor-α
revolutionized the modern management of patients with IBD. In spite of this, a proportion of …
revolutionized the modern management of patients with IBD. In spite of this, a proportion of …